The Potential Effect of Statins on Rituximab Immunotherapy

von Cragg, Mark S
Veröffentlicht 2008

Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal

von Erenpreisa, Jekaterina, Cragg, Mark S
Veröffentlicht 2013

Death by a thousand knives: Multiple BH3-only proteins are required for maximal apoptosis triggered through the BCR

von Carter, Matthew J., Cragg, Mark S.
Veröffentlicht in Mol Cell Oncol (2015)

Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy

von Roghanian, Ali, Cragg, Mark S., Frendéus, Björn
Veröffentlicht in Oncoimmunology (2015)

Editorial: Roles of Fc Receptors in Disease and Therapy

von Ganesan, Latha P., Cragg, Mark S., Vidarsson, Gestur
Veröffentlicht in Front Immunol (2020)

Response: Superior B cell–depleting activity of type II anti-CD20 mAb is not due to activation of complement

von Beers, Stephen A., Cragg, Mark S., Glennie, Martin J.
Veröffentlicht 2008

Role of STAT1 in the breast

von Bailey, Sarah G., Cragg, Mark S., Townsend, Paul A.
Veröffentlicht 2012

Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB

von Stopforth, Richard J., Cleary, Kirstie L. S., Cragg, Mark S.
Veröffentlicht in J Clin Immunol (2016)

Novel antibodies targeting immune regulatory checkpoints for cancer therapy

von Lee, Chern Siang, Cragg, Mark, Glennie, Martin, Johnson, Peter
Veröffentlicht 2013

Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

von Marshall, Michael J. E., Stopforth, Richard J., Cragg, Mark S.
Veröffentlicht in Front Immunol (2017)

Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

von Cragg, Mark S, Kuroda, Junya, Puthalakath, Hamsa, Huang, David C. S, Strasser, Andreas
Veröffentlicht 2007

Macroautophagy-aided elimination of chromatin: Sorting of waste, sorting of fate?

von Erenpreisa, Jekaterina, Huna, Anda, Salmina, Kristine, Jackson, Thomas R., Cragg, Mark S.
Veröffentlicht 2012

Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges

von Lim, Sean H., Beers, Stephen A., Al-Shamkhani, Aymen, Cragg, Mark S.
Veröffentlicht in Clin Cancer Res (2024)

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

von Liu, Rena, Oldham, Robert J., Teal, Emma, Beers, Stephen A., Cragg, Mark S.
Veröffentlicht in Antibodies (Basel) (2020)

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

von Cragg, Mark S., Jansen, Elisa S., Cook, Michele, Harris, Claire, Strasser, Andreas, Scott, Clare L.
Veröffentlicht 2008

Antibody distance from the cell membrane regulates antibody effector mechanisms

von Cleary, Kirstie L.S., Chan, H.T. Claude, James, Sonja, Glennie, Martin J., Cragg, Mark S.
Veröffentlicht in J Immunol (2017)

Genetic dissection of a major haplotype associated with arthritis reveal FcγR2b and FcγR3 to act additively

von Vaartjes, Daniëlle, Klaczkowska, Dorota, Cragg, Mark S, Nandakumar, Kutty Selva, Bäckdahl, Liselotte, Holmdahl, Rikard
Veröffentlicht in Eur J Immunol (2020)

The “virgin birth”, polyploidy, and the origin of cancer

von Erenpreisa, Jekaterina, Salmina, Kristine, Huna, Anda, Jackson, Thomas R., Vazquez-Martin, Alejandro, Cragg, Mark S.
Veröffentlicht in Oncoscience (2014)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

von Reddy, Venkat, Cambridge, Geraldine, Isenberg, David A., Glennie, Martin J., Cragg, Mark S., Leandro, Maria
Veröffentlicht in Arthritis Rheumatol (2015)

The Cancer Aneuploidy Paradox: In the Light of Evolution

von Salmina, Kristine, Huna, Anda, Kalejs, Martins, Pjanova, Dace, Scherthan, Harry, Cragg, Mark S., Erenpreisa, Jekaterina
Veröffentlicht in Genes (Basel) (2019)